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How alum works
For more than 70 years, alum has been 
used as a trusty aide to improve antibody 
responses to vaccines. But how this 
aluminum-containing compound boosts 
the response to vaccines has been a 
mystery. On page 869, Kool et al. ex-
pose its mysterious mechanism; they find 
that alum causes cells to produce a stim-
ulator of dendritic cells (DCs).
DCs were once the favored hypo-
thetical link between alum and B cells, 
as they activate CD4+ T cells, which can 
then enhance B cell activation and anti-
body production. But DCs were later 
dismissed when it was found that they 
were not stimulated by alum in vitro.
These in vitro results are now shown 
to be a red herring by Kool et al., who 
find that alum activates DCs in vivo by 
provoking the secretion of uric acid—
a molecule that is triggered by tissue 
and cell trauma. The injection of alum, 
the group found, induced an influx of 
neutrophils and inflammatory cytokines 
and chemokines—a combination that 
was previously seen in response to the 
injection of uric acid into mice.
In mice injected with antigens mixed 
with alum, uric acid levels increased 
within hours. The uric acid might be 
released by the cells’ lining the body’s 
cavities that turn necrotic after contact-
ing the alum. The absence of these uric 
acid sources in in vitro assays might have 
led to the previous misleading results.
In response to the uric acid, inflam-
matory monocytes flocked to the injection 
site, took up the antigens, and broke 
them down into T cell–stimulating 
epitopes. The monocytes then migrated 
to lymph nodes, where they matured 
into DCs and activated CD4+ T cells.
Without alum, the antigens were not 
taken up at the injection site. Still, they 
eventually reached lymph nodes via the 
flowing lymph. The resident node DCs, 
however, did not process the alum-free 
antigens efficiently or express T cell co-
stimulating receptors. The resulting 
subdued immunity was similar to that 
seen in mice that were depleted of inflam-
matory monocytes or those injected with 
enzymes that degrade uric acid. 
OX40: a win–win path 
to tumor immunity
Regulatory T (T reg) cells prevent autoimmunity by keeping self-reactive 
effector T cells in check, but this suppression becomes counterproductive 
when the effector cells are prevented from attacking tumors. Piconese 
et al. now show on page 825, however, that tumor immunity can be 
achieved without risking autoimmunity simply by stimulating a T cell 
surface protein called OX40.
A major challenge in tumor immunotherapy lies in breaking T reg 
cell–mediated tumor tolerance without inducing organism-wide 
autoimmunity or compromising immune surveillance. This goal has 
remained elusive because current methods used to derail T reg cell 
activity—such as depleting them using antibodies to a major T reg cell 
surface marker, CD25—also target effector T cells, thereby preventing 
tumor immunity and perhaps immunity to pathogens. T reg cell depletion also provokes conversion of effector 
T cells into T reg cells, thus worsening the initial immune suppression.
Piconese et al. sought a different approach by targeting OX40 because its stimulation suppresses T reg cell 
function while enhancing effector T cell survival and activity in vitro. Mice injected with agonistic anti-OX40 
antibody before their injection with a carcinoma cell line efficiently rejected the tumor. Anti-OX40 injection 
also melted established tumors and promoted lasting immunity against the cancer.
Suppression of T reg cells in the tumor enhanced the migration of tumor-infiltrating dendritic cells (DCs) and 
allowed the DCs to carry tumor antigens to the draining lymph node, where they could then activate a new 
wave of tumor-reactive T cells. Meanwhile, the triggering of OX40 on effector T cells also enhanced tumor immunity, 
thus providing a double benefit. Mice injected twice with anti-OX40 antibody showed no evidence of autoimmunity 
and no change in T reg cell number, so OX40 may be a promising target for cancer immunotherapy. 
Mice injected with agonist anti-OX40 antibody remain tumor-
free after injection with cancer cells.
Mice injected with antigens mixed with alum 
produce uric acid that then attracts monocytes.